These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 4042519)

  • 21. Amiodarone pharmacokinetics. III. Influence of thyroid dysfunction on amiodarone absorption and disposition.
    Weir SJ; Ueda CT
    J Pharmacol Exp Ther; 1988 Sep; 246(3):1026-32. PubMed ID: 3418508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
    Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
    Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of different thyroid status on the pharmacokinetics of diazepam].
    Xu F; Zhang Y; Lou Y
    Yao Xue Xue Bao; 1998 Aug; 33(8):571-5. PubMed ID: 12016895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Crossover pharmacokinetic study of quinupramine in 6 subjects].
    Bouquet S; Lefebvre MA; Girault J; Fourtillan JB
    Encephale; 1982; 8(4):449-63. PubMed ID: 7151737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipyrine and doxycycline pharmacokinetics in patients with thyroid disorders.
    Nayak VK; Desai NK; Kshirsagar NA; Bhandarkar SD; Satoskar RS
    J Postgrad Med; 1991 Jan; 37(1):5-8. PubMed ID: 1941694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
    Kruljac I; Solter D; Vrkljan AM; Solter M
    Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral versus intravenous vinorelbine: clinical safety profile.
    Gebbia V; Puozzo C
    Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic clearance and production rates of 3,3',5-triiodothyronine in hyperthyroid, euthyroid, and hypothyroid subjects.
    Smallridge RC; Wartofsky L; Desjardins RE; Burman KD
    J Clin Endocrinol Metab; 1978 Aug; 47(2):345-9. PubMed ID: 263302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An improved method for plasma methimazole assay and its clinical application].
    Okuno A; Yano K; Inyaku F; Suzuki Y; Taguchi T; Murata M; Momotani N
    Nihon Naibunpi Gakkai Zasshi; 1984 Aug; 60(8):985-94. PubMed ID: 6510539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers.
    Trinchard-Lugan I; Ho-Nguyen Q; Bilham WM; Buraglio M; Ythier A; Munafo A
    Eur Cytokine Netw; 2001; 12(3):391-8. PubMed ID: 11566619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of disorders of thyroid function on phenazone pharmacokinetics].
    Bolanowski M; Orzechowska-Juzwenko K; Gruszka S; Szymczak J
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):136-9. PubMed ID: 2216953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and bioavailability of digitoxin by a specific assay.
    MacFarland RT; Marcus FI; Fenster PE; Graves PE; Perrier D
    Eur J Clin Pharmacol; 1984; 27(1):85-9. PubMed ID: 6489430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of atenolol kinetics when hypothyroidism is corrected.
    Levesque H; Richard MO; Fresel J; Gancel A; Moore N; Courtois H
    Eur J Clin Pharmacol; 1990; 38(2):185-8. PubMed ID: 2338117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of chlorpheniramine.
    Rumore MM
    Drug Intell Clin Pharm; 1984 Sep; 18(9):701-7. PubMed ID: 6383755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.